Results 11 to 20 of about 214 (125)

SARS-CoV-2: A potential trigger of dermato-neuro syndrome in a patient with scleromyxedema [PDF]

JAAD Case Reports, 2021
Mike Fritz, BS, Daniel Tinker, MD, Alex W. Wessel, BS, Gabriela M. Morris, MD, Linda Goldenberg, MSN, RN, Mark Fesler, MD, Lokesh Rukmangadachar, MD, MS, M. Yadira Hurley, MD   +7 more
doaj   +2 more sources

Discrete papular lichen myxedematosus successfully treated with isotretinoin [PDF]

JAAD Case Reports
Alexa Figueroa Baiges, BS, Nina Punyamurthy, MD, Alexander M. Maley, MD   +2 more
doaj   +2 more sources

An unusual case of granulomatous scleromyxedema [PDF]

JAAD Case Reports, 2022
Lauren Michelle, BA, Sara Sabeti, BS, Katerina Yale, MD, Brittany Urso, MD, Bonnie Lee, MD, Janellen Smith, MD   +5 more
doaj   +2 more sources

Coexistence of mucinous nevus and multiple collagenoma with unilateral, dermatomal, and multi segmental distribution. [PDF]

Clin Case Rep, 2023
Deposition of amorphous materials in the high‐power field. Key Clinical Message Connective tissue nevus is a hamartoma composed of excess amounts of one or several components of the dermis, such as collagen, elastin, and proteoglycans. This report introduces a 14‐year‐old girl with grouped flesh color papules and skin color nodules distributed ...
Faghihi G, Moeine R, Mohaghegh F, Rajabi P, Shahriarirad R.   +4 more
europepmc   +2 more sources

Euthyroid Pretibial Mucinous Dermatoses: A Systematic Review of Current Evidence and the Controversy Surrounding Their Classification [PDF]

Acta Dermato-Venereologica
Ghassan Barnawi, Raquel Lazarowitz, Ammar Saed Aldien, Tammam Alanezi, Ivan V. Litvinov   +4 more
doaj   +2 more sources

A case of nevoid follicular mucinosis in a child [PDF]

JAAD Case Reports, 2021
David M. Weiner, AB, Ashley K. Clark, MD, Amanda T. Moon, MD, Paul L. Haun, MD, Sara S. Samimi, MD   +4 more
doaj   +2 more sources

A rare case of acral persistent papular mucinosis. [PDF]

Clin Case Rep, 2020
In patients with asymptomatic papules of hands and feet, a clinical differential of acral persistent papular mucinosis should be thought of. Abstract In patients with asymptomatic papules of hands and feet, a clinical differential of acral persistent papular mucinosis should be thought of.
Toh JJ, Goh NS, Wang DY.
europepmc   +2 more sources

Identifying the potential origin of mucin in primary cutaneous mucinoses—A retrospective study and analysis using histopathology and multiplex fluorescence staining

Journal of the European Academy of Dermatology and Venereology, Volume 37, Issue 7, Page 1302-1310, July 2023., 2023
Abstract Background Primary cutaneous mucinoses (PCM) are rare diseases characterized by dermal or follicular mucin deposits. Objectives A retrospective study characterizing PCM to compare dermal with follicular mucin to identify its potential origin on a single‐cell level.
S. Steinmann, C. Guillet, P. F. Cheng, M. P. Levesque, R. Dummer, I. Kolm, J. T. Maul   +6 more
wiley   +1 more source

Assessment of stigma related to visible skin diseases: a systematic review and evaluation of patient‐reported outcome measures

Journal of the European Academy of Dermatology and Venereology, Volume 36, Issue 4, Page 499-525, April 2022., 2022
Abstract Misconceptions about visible skin diseases are widespread, and patients often face discrimination and stigmatization due to their condition. The associated negative health and psychosocial consequences of stigmatization in skin diseases have prompted an increase in research activity in recent times, resulting in a wide variety of assessment ...
C. Luck‐Sikorski, P. Roßmann, J. Topp, M. Augustin, R. Sommer, N.A. Weinberger   +5 more
wiley   +1 more source

Current development and future perspective of IDH1 inhibitors in cholangiocarcinoma

Liver Cancer International, Volume 3, Issue 1, Page 17-31, February 2022., 2022
Abstract Background and Aims Biliary tract cancer (BTC) represents a major public health problem due to its increasing rates of incidence and mortality, especially the intrahepatic cholangiocarcinoma (IHCCA) subtype. First line palliative systemic treatment with cisplatin and gemcitabine has been the unique level IA evidence option until last few years
Jorge Adeva
wiley   +1 more source